Anti-CRR9 mAbs to Treat Therapy-Resistant Cancer

Abstract

CRR9 monoclonal antibodies kill tumors & re-sensitize them to chemotherapy independently of oncogenic drivers, including KRas-driven, ovarian, lung & pancreatic tumors. We have a validated target, and established MOA & in vivo POC data.

Our novel CRR9-inhibiting human monoclonal antibodies:

  • are stable, scalable, fully human IgG1 lead inhibitors
  • specifically, target the most relevant CRR9 epitope & tumor tissues
  • don’t have measurable toxicity
  • hit one target, but multiple pathways
  • kill as monotherapy & are synergistic with apoptosis-inducing agents with potential for combination (chemo, radiation, targeted, and immune) therapy

Website

https://www.mcw.edu/-/media/MCW/Departments/Office-of-Technology-Development/OTD-Available-Technologies-No-1777-AntiCRR9-mAbs-to-Treat-Therapy-Resistant-Cancer.pdf

Contact Information

MCW Office of Technology Development: https://www.mcw.edu/departments/technology-development

Name: Kevin Boggs, Ph.D., MBA

Title: Director

Phone: (414) 955-4381

Email: kpboggs@mcw.edu